Cancer Letters
Volume 230, Issue 1 , Pages 25-32 , 8 December 2005

Enhancement by acrylamide of N-methyl-N-nitrosourea-induced rat mammary tumor development—possible application for a model to detect co-modifiers of carcinogenesis

Received 17 August 2004 ,Revised 26 November 2004 ,Accepted 15 December 2004.

References 

  1. Smith CJ, Perfetti TA, Rumple MA, Rodgman A, Doolittle DJ. ‘IARC group 2A Carcinogens’ reported in cigarette mainstream smoke. Food Chem. Toxicol. 2000;38:371–383
  2. The International Agency for Research on Cancer (IARC) Working Group on the evaluation of carcinogenic risks to humans—some industrial chemicals, Acrylamide, in: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 60, IARC, Lyon, 1994, pp. 389–433.
  3. Bergmark E. Hemoglobin adducts of acrylamide and acrylonitrile in laboratory workers, smokers and nonsmokers. Chem. Res. Toxicol. 1997;10:78–84
  4. Tareke E, Rydberg P, Karlsson P, Eriksson S, Tornqvist M. Analysis of acrylamide, a carcinogen formed in heated foodstuffs. J. Agric. Food Chem. 2002;50:4998–5006
  5. Takatsuki S, Nemoto S, Sasaki K, Maitani T. Determination of acrylamide in processed foods by LC/MS using column switching. Shokuhin Eiseigaku Zasshi. 2003;44:89–95
  6. Jezussek M, Schieberle P. A new LC/MS-method for the quantitation of acrylamide based on a stable isotope dilution assay and derivatization with 2-mercaptobenzoic acid. Comparison with two GC/MS methods. J. Agric. Food Chem. 2003;51:7866–7871
  7. Ahn JS, Castle L, Clarke DB, Lloyd AS, Philo MR, Speck DR. Verification of the findings of acrylamide in heated foods. Food Addit. Contam. 2002;19:1116–1124
  8. Roach JA, Andrzejewski D, Gay ML, Nortrup D, Musser SM. Rugged LC-MS/MS survey analysis for acrylamide in foods. J. Agric. Food Chem. 2003;51:7547–7554
  9. Becalski A, Lau BP, Lewis D, Seaman SW. Acrylamide in foods: occurrence, sources, and modeling. J. Agric. Food Chem. 2003;51:802–808
  10. Crofton KM, Padilla S, Tilson HA, Anthony DC, Raymer JH, MacPhail RC. The impact of dose rate on the neurotoxicity of acrylamide: the interaction of administered dose, target tissue concentrations, tissue damage, and functional effects. Toxicol. Appl. Pharmacol. 1996;139:163–176
  11. Lehning EJ, Persaud A, Dyer KR, Jortner BS, LoPachin RM. Biochemical and morphologic characterization of acrylamide peripheral neuropathy. Toxicol. Appl. Pharmacol. 1998;151:211–221
  12. Sickles DW, Stone JD, Friedman MA. Fast axonal transport: a site of acrylamide neurotoxicity?. Neurotoxicology. 2002;23:223–251
  13. Tyl RW, Friedman MA. Effects of acrylamide on rodent reproductive performance. Reprod. Toxicol. 2003;17:1–13
  14. Abramsson-Zetterberg L. The dose–response relationship at very low doses of acrylamide is linear in the flow cytometer-based mouse micronucleus assay. Mutat. Res. 2003;535:215–222
  15. Dearfield KL, Douglas GR, Ehling UH, Moore MM, Sega GA, Brusick DJ. Acrylamide: a review of its genotoxicity and an assessment of heritable genetic risk. Mutat. Res. 1995;330:71–99
  16. Bull RJ, Robinson M, Laurie RD, Stoner GD, Greisiger E, Meier JR, et al. Carcinogenic effects of acrylamide in Sencar and A/J mice. Cancer Res. 1984;44:107–111
  17. Bull RJ, Robinson M, Stober JA. Carcinogenic activity of acrylamide in the skin and lung of Swiss-ICR mice. Cancer Lett. 1984;24:209–212
  18. Friedman MA, Dulak LH, Stedham MA. A lifetime oncogenicity study in rats with acrylamide. Fundam. Appl. Toxicol. 1995;27:95–105
  19. Johnson KA, Gorzinski SJ, Bodner KM, Campbell RA, Wolf CH, Friedman MA, et al. Chronic toxicity and oncogenicity study on acrylamide incorporated in the drinking water of Fischer 344 rats. Toxicol. Appl. Pharmacol. 1986;85:154–168
  20. Fujita K, Ohnishi T, Sekine K, Iigo M, Tsuda H. Down-regulation of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx)-induced CYP1A2 expression is associated with bovine lactoferrin inhibition of MeIQx-induced liver and colon carcinogenesis in rats. Jpn. J. Cancer Res. 2002;93:616–625
  21. Hirose M, Takahashi S, Ogawa K, Futakuchi M, Shirai T, Shibutani M, et al. Chemoprevention of heterocyclic amine-induced carcinogenesis by phenolic compounds in rats. Cancer Lett. 1999;143:173–178
  22. Imaida K, Sano M, Tamano S, Asamoto M, Ogawa K, Futakuchi M, et al. Organ dependent enhancement of rat 3,2′-dimethyl-4-aminobiphenyl (DMAB) carcinogenesis by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP): positive effects on the intestine but not the prostate. Carcinogenesis. 2001;22:1295–1299
  23. Ogawa K, Iwasaki S, Esumi H, Fukushima S, Shirai T. Modification by 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) of 3,2′-dimethyl-4-aminobiphenyl (DMAB)-induced rat pancreatic and intestinal tumorigenesis. Cancer Lett. 1998;124:31–37
  24. VanderPloeg LC, Wolfrom DM, Welsch CW. Influence of caffeine on development of benign and carcinomatous mammary gland tumors in female rats treated with the carcinogens 7,12-dimethylbenz(a)anthracene and N-methyl-N-nitrosourea. Cancer Res. 1991;51:3399–3404
  25. Welsch CW. Caffeine and the development of the normal and neoplastic mammary gland. Proc. Soc. Exp. Biol. Med. 1994;207:1–12
  26. Allred CD, Allred KF, Ju YH, Clausen LM, Doerge DR, Schantz SL, et al. Dietary genistein results in larger MNU-induced, estrogen-dependent mammary tumors following ovariectomy of Sprague–Dawley rats. Carcinogenesis. 2004;25:211–218
  27. Gallo D, Ferrandina G, Giacomelli S, Fruscella E, Zannoni G, Morazzoni P, et al. Dietary soy modulation of biochemical parameters in DMBA-induced mammary tumors. Cancer Lett. 2002;186:43–48
  28. Tagliaferro AR, Ronan AM, Meeker LD, Thompson HJ, Scott AL. Cyclic food restriction, insulin and mammary cell proliferation in the rat. Carcinogenesis. 1997;18:2271–2276
  29. Kito K, Kihana T, Sugita A, Murao S, Akehi S, Sato M, et al. Incidence of p53 and Ha-ras gene mutations in chemically induced rat mammary carcinomas. Mol. Carcinog. 1996;17:78–83
  30. Yu M, Ryu DY, Snyderwine EG. Genomic imbalance in rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine. Mol. Carcinog. 2000;27:76–83
  31. Haag JD, Brasic GM, Shepel LA, Newton MA, Grubbs CJ, Lubet RA, et al. A comparative analysis of allelic imbalance events in chemically induced rat mammary, colon, and bladder tumors. Mol. Carcinog. 1999;24:47–56
  32. Imai T, Onose J, Hasumura M, Ueda M, Takizawa T, Hirose M. Sequential analysis of development of invasive thyroid follicular cell carcinomas in inflamed capsular regions of rats treated with sulfadimethoxine after N-bis(2-hydroxypropyl)nitrosamine-initiation. Toxicol. Pathol. 2004;32:229–236
  33. Hiasa Y, Ohshima M, Kitahori Y, Yuasa T, Fujita T, Iwata C. Promoting effects of 3-amino-1,2,4-triazole on the development of thyroid tumors in rats treated with N-bis(2-hydroxypropyl)nitrosamine. Carcinogenesis. 1982;3:381–384
  34. Yasuhara K, Koujitani T, Takegawa K, Nasu M, Onodera H, Takagi H, et al. Promoting effects of xylazine on development of thyroid tumors in rats initiated with N-bis(2-hydroxypropyl)nitrosamine and the mechanism of action. Carcinogenesis. 2001;22:613–618
  35. Fujimoto N, Sakai Y, Ito A. Increase in estrogen receptor levels in MNU-induced thyroid tumors in LE rats. Carcinogenesis. 1992;13:1315–1318

PII: S0304-3835(04)00996-6

doi: 10.1016/j.canlet.2004.12.019

Cancer Letters
Volume 230, Issue 1 , Pages 25-32 , 8 December 2005

Article Tools

* Image Usage & Resolution